Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Study Details
Study Description
Brief Summary
Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide for adult T-ALL/LBL. Compared to PDT-ALL-2016 for B-ALL, HDACi chidamide will be administrated from induction therapy to maintenance therapy, along with higher dose of consolidation regimen of cytarabine, methotrexate, cyclophosphamide.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
T-lymphoblastic lymphoma/leukemia is a neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast with scant cytoplasm, moderately condensed to dispersed chromatin, and inconspicuous nucleoli, involving bone marrow and blood or presenting with primary involvement of the thymus or of nodal or extranodal sites. T-ALL/LBL is generally considered a higher-risk disease than B-ALL. Compared to B-ALL, T-LBL/ALL is associated with a higher risk of induction failure, early relapse, and isolated CNS relapse.
Chidamide is a novel oral HDACi with promising activity in non-Hodgkin lymphoma (NHL). Chidamide, a new oral isotype-selective HDACi, approved in China for the treatment of R/R PTCL in December 2014. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide for adult T-ALL/LBL. Compared to PDT-ALL-2016 for B-ALL, HDACi chidamide will be administrated from induction therapy to maintenance therapy, along with higher dose of consolidation regimen of cytarabine, methotrexate, cyclophosphamide.
The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, Idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment (MRD1/d14, MRD2/d24, MRD3/d45, MRD4/pre-allo-HSCT) and maintenance regimen (chidamide, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
Induction Regimen-Pretreatment: dexamethasone, -3d to 0d; Induction regimen VICLD: VCR: d1, d8, d15, d22; IDA: d1, d8; CTX: 1g/m2, 1; PEG-asp: 2000-2500IU/m2, 1, 15; dexamethasone: 1-24; chidamide: 10mg/d, po, qd. Flow-based MRD assessment: d14, d24 during induction regimen, d45, and pre-HSCT. Salvage regimen VLCAM (MRD1/d24>1%): CTX, d25; AraC 50mg/m2, d25-31; 6-MP: 25-31, PEG-asp: 2500IU/m2, d26. Consolidation Module (CM)-CM1: AraC 3g/m2, q12h, d1-2, Dex: 10mg/m2, d1-2, PEG-asp: 2, 6-MP: d1-7, chidamide, po qd; CM2: MTX 5g/m2, 1, Dex: 10mg/m2, 1-2, PEG-asp: d2, 6-MP: 1-7, chidamide, po qd; CM3: CTX 1g/m2, 1-3, PEG-asp: 2, 6-MP: 1-7, chidamide, po qd. CM4-6: repeat CM 1-3. Re-Induction: VICLD after CM6. CM7-9: repeat CM1-3. Allo-HSCT: after CM3 when matched-related-donor (MRD), haploidentical related donor (HRD) or matched-unrelated-donor (MUD) available. Non-allo-HSCT: finish CM4-9 and CPOMP maintenance. Maintenance Module-CPOMP: chidamide, po qd for 24 months; Pred: for 12 months; VCR for 12 months; MTX: for 24m months; 6-MP for 24 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: PDT-ALL-LBL The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor. |
Drug: Dexamethasone
Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: vincristine
Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: Cyclophosphamide
CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: Idarubicin
IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: Pegaspargase
PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: Adriamycin
Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: Methotrexate
Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: 6-mercaptopurine.
Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: Etoposide
VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Other Names:
Drug: Cytarabine
AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Other Names:
Procedure: Bone marrow aspiration
Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
Other Names:
Procedure: Intrathecal injection
Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
Other Names:
Radiation: Radiation therapy
Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
Other Names:
Genetic: NGS
Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
Procedure: allogeneic hematopoietic stem cell transplantation
Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
Other Names:
Diagnostic Test: Flow-MRD
Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
Diagnostic Test: FISH
FISH will be added to PDT-ALL-LBL for bone marrow samples.
Diagnostic Test: Flow immunophenotyping
Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
Diagnostic Test: Karyotyping
Karyotyping will be performed in PDT-ALL-LBL protocol.
Drug: Chidamide
HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
Other Names:
Diagnostic Test: PET-CT scan
PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Event-Free-Survival [3 years]
3 years EFS of LBL/ALL patients enrolled in PDT-ALL-LBL
Secondary Outcome Measures
- Minimum residual disease after induction [3 months]
MRD after induction regimen of PDT-ALL-LBL protocol
- CR after Induction Therapy [3 months]
CR after induction regimen of PDT-ALL-LBL protocol
- Death in induction [3 months]
Dearth during induction regimen of PDT-ALL-LBL
- Adverse events [3 years]
AE of 3 years of LBL patients enrolled in PDT-ALL-LBL
- Relapse [3 years]
Cumulative incidence relapse rate of 3 years of LBL patients enrolled in PDT-ALL-LBL protocol
- Relapse free survival [3 years]
3 years RFS of LBL patients enrolled in PDT-ALL-LBL protocol
- Overall survival [3 years]
3 years OS of LBL patients enrolled in PDT-ALL-LBL protocol
Eligibility Criteria
Criteria
Inclusion Criteria:
-
14-55 years old;
-
LBL/ALL newly diagnosed;
-
signed written informed consent.
Exclusion Criteria:
-
Pregnant women;
-
History of pancreatitis;
-
History of diabetes;
-
History of active peptic ulcer disease in the past 6 months;
-
History of arteriovenous thrombosis in the past 6 months;
-
Severe active infection;
-
Allergic to any drugs in PDT-ALL-LBL protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Hematology, Nanfang Hospital | Guangzhou | Guangdong | China | 510515 |
Sponsors and Collaborators
- Nanfang Hospital of Southern Medical University
Investigators
- Study Chair: Qifa Liu, MD, Department of Hematology Nanfang Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PDT-ALL-LBL